The Growing Armamentarium Against EGFR Exon 20+ Non–Small Cell Lung Cancer
Joshua K. Sabari, MD, reviews the therapies available to treat patients with EGFR exon 20-positive non–small cell lung cancer.
Joshua K. Sabari, MD, assistant professor, Department of Medicine, NYU Grossman School of Medicine, reviews the therapies available to treat patients with EGFR exon 20-positive non–small cell lung cancer (NSCLC).
In recent years, there was an explosion of therapeutic opportunities for patients with EGFR exon 20 insertion mutant NSCLC, Sabari says. The two avenues of therapies are EGFR exon 20-directed tyrosine kinase inhibitors such as mobocertinib, which is a small molecule that specifically inhibits EGFR exon 20. Sabari explains that there are many other exon 20-specific TKIs in development, such as BDTX-189 and CLN-081. Older agents like poziotinib are also still effective for the treatment of this patient population.
Most recently, the FDA granted approval to amivantamab-vmjw (Rybrevant), an agent that has been shown to have activity in exon 20 insertion mutant disease.
FDA Grants Breakthrough Therapy Designation to Sunvozertinib in EGFR Exon20+ NSCLC
April 9th 2024Sunvozertinib was granted breakthrough therapy designation by the FDA for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer harboring an EGFR exon 20 insertion mutation.
Read More
Amivantamab/Lazertinib Still Effective in EGFRm NSCLC Despite Dose Interruptions
March 26th 2024According to a subset analysis of the phase 3 MARIPOSA trial, dose interruptions during the course of amivantamab and lazertinib treatment were still effective in EGFR-mutant non-small cell lung cancer.
Read More
Osimertinib Enhances Progression-Free Survival in Stage III NSCLC
February 19th 2024Osimertinib shows significant progression-free survival improvement in stage III EGFR-mutated non-small cell lung cancer post-chemoradiotherapy, marking a major advance in treatment options for this patient population.
Read More
